EGFR overexpression and mutation are frequently identified in metastatic non-small-cell lung cancer and are associated with poor prognosis.66 L858R is the most prevalent EGFR tyrosine kinase activating mutation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.